Want to see CNMD full AI Analyst Report?
CNMD Stock Chart & Stats
$44.35
$0.19(0.28%)
At close: 4:00 PM EST
$44.35
$0.19(0.28%)
Day’s Range― - ―
52-Week Range$31.44 - $56.64
Previous CloseN/A
Volume49.43K
Average Volume (3M)368.83K
Market Cap
$1.31B
Enterprise Value$1.91K
Total Cash (Recent Filing)$35.03M
Total Debt (Recent Filing)$860.87M
Price to Earnings (P/E)24.5
Beta0.60
Next Earnings
Jul 29, 2026EPS Estimate
1.11Next Dividend Ex-DateN/A
Dividend Yield1.91%
Share Statistics
EPS (TTM)1.77
Shares Outstanding30,109,194
10 Day Avg. Volume284,080
30 Day Avg. Volume368,831
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.22
Price to Sales (P/S)0.92
P/FCF Ratio8.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$38.80Price Target Upside-12.51% Downside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)4.34
Revenue Forecast (FY)$1.36B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Installed BaseCONMED’s business mixes capital equipment with single‑use consumables tied to procedures. Installed platforms create recurring per‑case demand and predictable replacement cycles, supporting durable revenue and cash flow generation even if procedure volumes fluctuate regionally.
Large AirSeal Runway And Platform MomentumAirSeal’s low current penetration against a multi‑million procedure market implies a multi‑year growth runway. Installed base growth drives recurring consumable sales and cross‑sell opportunities, making AirSeal a structural growth engine less sensitive to short quarterly swings in procedure volumes.
Proactive Balance‑sheet RepairManagement repurchased a large portion of convertible debt and put in place a term loan to refinance maturities. Reducing convertible exposure lowers dilution risk and improves creditor confidence, increasing financial flexibility and lowering refinancing uncertainty over the medium term.
Bears Say
Sharp TTM Revenue DeclineA roughly 30% TTM revenue decline is a material structural headwind: it compresses operating leverage, limits reinvestment capacity for R&D and commercial expansion, and raises execution risk. Restoring topline momentum may require sustained share gains or successful adoption of growth platforms.
Compressed Net Margins And ReturnsRelatively low net margins and modest returns constrain the company’s ability to self‑fund growth and reduce the cushion against pricing pressure or cost inflation. Even with solid gross margins, operating and net margin compression limit long‑term earnings resilience and investor return potential.
Working‑capital Strain And Weaker Operating Cash FlowA sharp quarter‑to‑quarter drop in operating cash flow plus rising AR and inventory days signals working‑capital pressure. This reduces near‑term liquidity, forces higher funding needs around seasonal or inventory builds, and can constrain discretionary investment and buyback flexibility until conversion normalizes.
Conmed News
CNMD FAQ
What was Conmed’s price range in the past 12 months?
Conmed lowest stock price was $31.44 and its highest was $56.63 in the past 12 months.
What is Conmed’s market cap?
Conmed’s market cap is $1.31B.
When is Conmed’s upcoming earnings report date?
Conmed’s upcoming earnings report date is Jul 29, 2026 which is in 7 days.
How were Conmed’s earnings last quarter?
Conmed released its earnings results on Apr 29, 2026. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.819 by $0.071.
Is Conmed overvalued?
According to Wall Street analysts Conmed’s price is currently Overvalued.
Does Conmed pay dividends?
Conmed pays a Quarterly dividend of $0.2 which represents an annual dividend yield of 1.91%. See more information on Conmed dividends here
What is Conmed’s EPS estimate?
Conmed’s EPS estimate is 1.11.
How many shares outstanding does Conmed have?
Conmed has 30,109,194 shares outstanding.
What happened to Conmed’s price movement after its last earnings report?
Conmed reported an EPS of $0.89 in its last earnings report, beating expectations of $0.819. Following the earnings report the stock price went up 1.947%.
Which hedge fund is a major shareholder of Conmed?
Currently, no hedge funds are holding shares in CNMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Conmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$38.80 (-12.51% Downside)
$38.80 (-12.51% Downside)
Hedge Fund Trend
Increased
By 264.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.21%
12-Months-Change
Fundamentals
Return on Equity
1.91%
Trailing 12-Months
Asset Growth
0.75%
Trailing 12-Months
Company Description
Conmed
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
CNMD Stock 12 Month Forecast
Average Price Target
$38.80
▼(-12.51% Downside)
Technical Analysis
Artivion
―
Integra Lifesciences
―
Ufp Technologies
―
AdaptHealth
―
PROCEPT BioRobotics
―
Ownership Overview
0.19% Insiders
39.82% Mutual Funds
0.52% Other Institutional Investors
31.76% Public Companies and
Individual Investors